Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Mahonia fortunei extract is a botanical product derived from the Chinese Mahonia plant, a species traditionally utilized in Chinese herbal medicine (CHM). Recent systems pharmacology and multi-omics research has identified this extract as a potential therapeutic candidate for hepatocellular carcinoma (HCC). The extract contains various bioactive alkaloids, such as berberine, which contribute to its pharmacological profile. It exerts anti-cancer effects by modulating specific hub genes, including AKR1B10, HMGCR, and THBS1, and influencing critical signaling pathways such as TNF, IL-17, and MAPK. Functional assays indicate that the extract suppresses the proliferation and migration of HCC cells while simultaneously inducing apoptosis and ferroptosis, suggesting a multi-target mechanism of action suitable for precision ethnopharmacology.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on mahonia fortunei extract.